Sunesis Pharmaceuticals, Inc. (SNSS) Rated #1 for gains in 2013 based of the following report:
Announced enrollment plans for additional 225 acute myeloid leukemia patients in its ongoing (phase III) study of vasaroxin. Favorable outlook on upsizing as it was based on efficacy data trending in the "promising zone"and significantly improves the trials odds of success.
Physicians noted use of vasaroxin likely will extend beyond the refractory AML setting such as first line settings when the patients are at high risk of relapse or have cardiovascular issues.
Sunesis Pharmaceuticals, Inc. estimates that vasaroxin can likely achieve peak annual sales of $700 million.
Dan Swisher - Chief Executive Officer for Sunesis Pharmaceuticals, Inc. said this: SNS has the cash through 2014, which is beyond several key data milestones. (low chance of dilution prior to run up)
Further he stated: "Our focus is on Vosaroxin, this is unique anti-cancer drug. We've got full worldwide rights to it and its being pursued in a late-stage hematology indication in relapsed refractory AML, very well powered trial"
RBC Capital believes that Phase III data for Valor’s Vosaroxin for AML could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.
MARKET OUTPERFORM price target $20
Using due diligence of your own you will probably agree with this report.